PEA1 Cell Line
Invented by Simon Langdon at Cancer Research UK Edinburgh Centre
PEA2 Cell Line
Invented by Simon Langdon from The University of Edinburgh
Invented at Cancer Research UK Edinburgh Centre
- Datasheet
- References (8)
- Inventor Info
Info
| Catalogue Number | 151679 |
| Host | Human |
| Tissue | Ovary |
| Disease Keywords | Adenocarcinoma |
| Model | Tumour line |
| Relevance | The PEA2 cell line is one of nine from the PE ovarian adenocarcinoma panel (derived from 4 patients at varying stages of ovarian cancer, isolated from various malignant sites, and at various treatment stages) which provides a model system for research into the mechanism of oestrogen action on ovarian adenocarcinoma tumour cells, and for the study of efficacy and toxicity of oestrogen protagonists. PEA2 is an adherent cell line derived from a malignant effusion from the peritoneal ascites of a patient with a poorly differentiated adenocarcinoma. PEA2 was collected on relapse after treatment with cisplatin and prednimustine. PEA2 exhibits poor growth in semi-solid medium (agar). PEA2 is from the same patient as the PEA1 cell line |
| Research Area | Cancer, Drug Discovery & Development |
| Growth/Phenotype Keywords | Adherent |
| Recommended Growing Conditions | Split sub-confluent cultures (70-80%) 1:4 to 1:10 seeding at 2- 3 x 104 cells/cm2 using 0.25% trypsin or trypsin/EDTA; 5% CO2; 37°C. Doubling time approximately 66 hours. RPMI-1640 + 2mM Glutamine + 2mM Sodium Pyruvate + 10% Foetal Bovine Serum. |
| Cellosaurus ID | CVCL_2683 |
PEO1 Cell Line
Invented by Simon Langdon at Cancer Research UK Edinburgh Centre
PEO4 Cell Line
Invented by Simon Langdon at Cancer Research UK Edinburgh Centre
PEO6 Cell Line
Invented by Simon Langdon at Cancer Research UK Edinburgh Centre
PEO14 Cell Line
Invented by Simon Langdon at Cancer Research UK Edinburgh Centre
PEO16 Cell Line
Invented by Simon Langdon at Cancer Research UK Edinburgh Centre
PEO23 Cell Line
Invented by Simon Langdon at Cancer Research UK Edinburgh Centre
PEO1-CDDP Cell Line
Invented by Simon Langdon at Cancer Research UK Edinburgh Centre
Antigen/Gene or Protein Targets: Human ovarian cancer; oestrogen receptor, drug resistance, cisplatin resistance
0
reviews
2
references
1
supplier
TO14 Cell Line
Invented by Simon Langdon at Cancer Research UK Edinburgh Centre
References: 8 entries
Matassa et al. 2016. Cell Death Differ. :. PMID: 27206315.
Oxidative metabolism drives inflammation-induced platinum resistance in human ovarian cancer.
Europe PMC ID: 27206315
Beaufort et al. 2014. PLoS One. 9(9):e103988. PMID: 25230021.
Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.
Europe PMC ID: 25230021
Langdon et al. 1990. Br J Cancer. 62(2):213-6. PMID: 2386737.
Oestrogen receptor expression and the effects of oestrogen and tamoxifen on the growth of human ovarian carcinoma cell lines.
Europe PMC ID: 2386737
Langdon et al. 1988. Cancer Res. 48(21):6166-72. PMID: 3167863.
Characterization and properties of nine human ovarian adenocarcinoma cell lines.
Europe PMC ID: 3167863
Add a reference
References: 8 entries
Matassa et al. 2016. Cell Death Differ. :. PMID: 27206315.
Oxidative metabolism drives inflammation-induced platinum resistance in human ovarian cancer.
Beaufort et al. 2014. PLoS One. 9(9):e103988. PMID: 25230021.
Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.
Langdon et al. 1990. Br J Cancer. 62(2):213-6. PMID: 2386737.
Oestrogen receptor expression and the effects of oestrogen and tamoxifen on the growth of human ovarian carcinoma cell lines.
Langdon et al. 1988. Cancer Res. 48(21):6166-72. PMID: 3167863.
Characterization and properties of nine human ovarian adenocarcinoma cell lines.
Add a reference
